Inventiva’s Lanifibranor On NASH Path After Phase II Success In NAFLD Patients With Diabetes
But All Eyes On NASH
Executive Summary
The French biotech’s PPAR agonist has significantly reduced liver fat in non-alcoholic fatty liver patients with type 2 diabetes in a mid-stage trial, raising hopes for success in an ongoing pivotal program in non-alcoholic steatohepatitis.